Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up PURPOSE: Unlike nodal follicular lymphoma (NFL), Primary cutaneous follicular lymphomas (PCFLs) rarely express Bcl-2 ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

"Random skin biopsies are utilized when there is a sufficiently high concern of the diagnosis in the patient and they do not have overt clinical findings suggestive of the diagnosis. In those cases, ...

Please provide your email address to receive an email when new articles are posted on . With new developments in the treatment of follicular lymphoma, such as chimeric antigen receptor T-cell ...

With a new FDA nod, BeiGene has filled the follicular lymphoma approval gap for BTK inhibitors. Thursday, the FDA doled out an accelerated approval for BeiGene’s Brukinsa to be used alongside Roche’s ...

The FDA has granted accelerated approval to subcutaneous treatment with mosunetuzumab (Lunsumio VELO™), a CD20xCD3 bispecific antibody, for adult patients with relapsed or refractory follicular ...

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or more prior treatments. The U.S. Food and Drug Administration (FDA) has ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...